InflaRx N.V. (IFRX)
| Previous close | 1.0800 |
| Open | 1.2500 |
| Bid | 1.2600 x 3200 |
| Ask | 1.2700 x 1000 |
| Day's range | 1.1400 - 1.2500 |
| 52-week range | 0.7760 - 5.6860 |
| Volume | |
| Avg. volume | 192,712 |
| Market cap | 54.314M |
| Beta (5Y monthly) | 0.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2570 |
| Earnings date | 23 Mar 2022 - 28 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.13 |
- Globe Newswire
InflaRx to Present at the H.C. Wainwright Global Investment Conference
JENA, Germany, May 17, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will give a company presentation at the upcoming H.C. Wainwright Global Investment Conference. The hybrid conference will be held in person in Miami, Florida and virtually from May 23rd to May 26th. InflaRx will present in person on Wednesday, May 25th at 10:30 AM EDT /
- Globe Newswire
InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic Update
Quarter highlighted by progress with vilobelimab in several indications: Encouraging Phase III topline results reported in patients with severe COVID-19; discussions with regulatory authorities already underwayFinal data from Phase IIa open-label study in patients with pyoderma gangrenosum presented at 2022 AAD Annual Meeting; end-of-Phase II meeting with FDA scheduled for mid-2022In Phase II trial in cutaneous squamous cell carcinoma, second dosing cohort of combination arm started; enrollment
- Simply Wall St.
Here's Why We're Not Too Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
